Cellectis Announces Presentations at Upcoming Conferences

NEW YORK--()--Regulatory News:

Cellectis (Alternext: ALCLS – Nasdaq: CLLS), a biopharmaceutical company focused on the development of gene edited, next generation CAR T-cell product candidates for the treatment of cancer, today announced presentations at the following upcoming banking conferences and events:

Goldman Sachs Biotech and Emerging Pharma Symposium
London, September 11, 2015

Bank of America Merrill Lynch Global Healthcare Conference
London, September 16, 2015 (Presentation time: 9:45AM)

Morgan Stanley Global Healthcare Conference
New York City, September 18, 2015

Cellectis Investor and Analyst Day NYC
New York City, September 22, 2015 (Presentation time: 8:00AM)

Ladenburg Thalmann Healthcare Conference
New York City, September 29, 2015 (Presentation time: 4:00PM)

Leerink Immuno-Oncology Roundtable
New York City, October 1, 2015

Cellectis Investor and Shareholder Day Paris
Paris, October 5, 2015 (Presentation time: 6:00PM)

About Cellectis

Cellectis is a biopharmaceutical company focused on developing immunotherapies based on gene edited CAR T-cells (UCART). The company’s mission is to develop a new generation of cancer therapies based on engineered T-cells. Cellectis capitalizes on its 15 years of expertise in genome engineering - based on its flagship TALEN® products and meganucleases and pioneering electroporation PulseAgile technology - to create a new generation of immunotherapies. CAR technologies are designed to target surface antigens expressed on cells. Using its life-science-focused, pioneering genome-engineering technologies, Cellectis’ goal is to create innovative products in multiple fields and with various target markets. Cellectis S.A. is listed on the Nasdaq market (ticker: CLLS) and on the NYSE Alternext market (ticker: ALCLS). To find out more about us, visit our website: www.cellectis.com

TALEN® is a registered trademark owned by the Cellectis Group.

Contacts

Media
Jennifer Moore, VP Communications
Phone: 917-580-1088
email: media@cellectis.com
or
Caitlin Kasunich / Dixon Moretz
KCSA Strategic Communications
212.896.1241 / 212.896.1251
ckasunich@kcsa.com / dmoretz@kcsa.com
or
Investor relations:
Simon Harnest, VP Finance and Investor Relations
Phone: 646-385-9008
email: simon.harnest@cellectis.com

Release Summary

Cellectis Announces Presentations at Upcoming Conferences

Contacts

Media
Jennifer Moore, VP Communications
Phone: 917-580-1088
email: media@cellectis.com
or
Caitlin Kasunich / Dixon Moretz
KCSA Strategic Communications
212.896.1241 / 212.896.1251
ckasunich@kcsa.com / dmoretz@kcsa.com
or
Investor relations:
Simon Harnest, VP Finance and Investor Relations
Phone: 646-385-9008
email: simon.harnest@cellectis.com